Track the FIVE PRIME THERAPEUTICS INC stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €12bn. The latest transaction was disclosed on 8 February 2016 (Cession). Among the most active insiders: Sarena Francis Willard. Every trade is openly available.
25
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate FIVE PRIME THERAPEUTICS INC Buy (bullish), based on 21 analysts. Average price target: US$260.48.
Fundamental score
Ranked 15,025 of 29,065 companies
51.1
score / 100
Value
44
Quality
59
FCF yld3.4%
Earn yld3.0%
EV/EBITDA21.6x
ROE21%
Gross mgn36%
Net mgn7.5%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.